The idea was based on the high quantity of transforming growth factor β 1 (TGFB1) and mimecan in AT EVs of subjects with obesity, as well as elevated levels of TGFB1- and mimecan-containing EVs in the plasma of subjects with obesity and diabetes. The gene discussed is TGFB1; the disease is obesity disorder.